|
US2016022571A1
|
|
Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
|
|
WO2014160167A1
|
|
Implantable drug delivery compositions comprising aromatic polyurethanes and methods of treatment thereof
|
|
WO2014160026A2
|
|
Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof
|
|
CN105101953A
|
|
Implantable drug delivery compositions and methods of treatment thereof
|
|
CA2853251A1
|
|
Implantable rasagiline compositions and methods of treatment thereof
|
|
CA2853249A1
|
|
Implantable tizanidine compositions and methods of treatment thereof
|
|
MX2011003300A
|
|
Implantable device for the delivery of octreotide and methods of use thereof.
|
|
BRPI0919465A2
|
|
implantable device for risperidone release and methods of use of risperidone
|
|
UA103635C2
|
|
Implantable device for the delivery of risperidone and method of use thereof
|
|
WO2010039643A1
|
|
Implantable device for the delivery of histrelin and methods of use thereof
|
|
WO2009158412A2
|
|
Sustained delivery of exenatide and other polypeptides
|
|
US2010022450A1
|
|
Octreotide implant having a release agent and uses thereof
|
|
WO2009111555A1
|
|
Combination treatment for bladder cancer comprisining valrubicin and trospium chloride
|
|
WO2009108778A1
|
|
Sulfonic acid and aldehyde condensation polymers for the treatment and prevention of hpv
|
|
US2009098182A1
|
|
Long term drug delivery devices with polyurethane based polymers and their manufacture
|
|
US2009035343A1
|
|
Delivery of dry formulations of octreotide
|
|
EP2139533A2
|
|
Implant device release agents and methods of using same
|
|
EP1773293A2
|
|
Compositions and methods for treating central precocious puberty
|
|
AU2003212585A1
|
|
Methods of preparation of the 2-(7-chloro-1,8-naphthyridine-2YL)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
|
